Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT06873828

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06873828
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06873828. Non-randomized; no masking; primary purpose diagnostic. Start 2025-03 (anticipated); primary completion 2025-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
Acronym
ATP-HCM
Condition
Hypertrophic Cardiomyopathy
Intervention (Device)
ATP-C135
Intervention (Device)
ATP-C75
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct06873828
Content hash
625dd39bd9a5c470b84962ab004ff5783e06de15300efd075aef1b91dc59a46f